autores
- xmlui.general.dspace_homexmlui.ArtifactBrowser.ConfigurableBrowse.trail.metadata.author
- Inicio
- autores
Autores
Mostrando ítems 1-3 de 3
-
A prime-boost combination of a three-protein cocktail and multiepitopic MVA as a vaccine against Babesia bigemina elicits neutralizing antibodies and a Th1 cellular immune response in mice
Montenegro, Valeria Noely; Jaramillo Ortiz, Jose; Paoletta, Martina; Gravisaco, María José; Del Medico Zajac, Maria Paula; Garanzini, Debora Patricia; Valenzano, Magali Nicole; Calamante, Gabriela; Wilkowsky, Silvina Elizabeth (Elsevier, 2022-09)In the intraerythrocytic protozoan parasites of the genus Babesia both innate and adaptive immune responses are necessary to confer protection against clinical disease. In particular, the adaptive immune response involves ... -
Estrategia de inmunoprofilaxis para la prevención de la rabia paresiante utilizando un virus canarypox recombinante = Immunoprophylaxis strategy for the prevention of paralytic rabies using a recombinant canarypox virus
Garanzini, Debora Patricia; Rossner, Maria Victoria; Stahringer, Rodolfo Carlos; Micucci, Matías; Perez, Oscar; Del Medico Zajac, Maria Paula; Russo, Susana; Calamante, Gabriela (Servicio Nacional de Sanidad y Calidad Agroalimentaria (SENASA), 2015-03)La rabia paresiante es una enfermedad causada por el virus rábico transmitido por el vampiro común. En el norte de nuestro país, se registran anualmente un número limitado de casos por lo que es necesaria la implementación ... -
The MVA vector expressing the F protein of bovine respiratory syncytial virus is immunogenic in systemic and mucosal immunization routes = El vector viral MVA que expresa la proteína F del virus respiratorio sincicial bovino es inmunogénico al administrarse por vía sistémica y por mucosas
Ferella, Alejandra; Mozgovoj, Marina Valeria; Garanzini, Debora Patricia; Dus Santos, Maria Jose; Calamante, Gabriela; Del Medico Zajac, Maria Paula (Elsevier, 2023-12)Bovine respiratory syncytial virus (BRSV) affects both beef and dairy cattle, reaching morbidity and mortality rates of 60---80% and 20%, respectively. The aim of this study was to obtain a recombinant MVA expressing the ...